Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03311516
Other study ID # 2017-A02414-49
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 10, 2019
Est. completion date June 2021

Study information

Verified date July 2020
Source Central Hospital, Nancy, France
Contact SIHAM BENZIRAR
Phone 0033383155028
Email s.benzirar@chru-nancy.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to evaluate the effect of insulin therapy when the bolus dose of insulin is calculated on the basis of protein and fat content in food intake, in addition to that of carbohydrates in T1D patients treated by insulin pump. The study is planned to recruit 150 patients with type1 diabetes already practicing functional insulin therapy based on carbohydrate counting in meals. We will therefore study the effect on continuous glucose measured by subcutaneous sensor, of meal bolus adjustments by comparing two groups of T1D patients:

- Groupe A takes into account the lipid and protein content in addition to the carbohydrate content

- Group B takes into account the carbohydrate content only At randomization, all patients receive dietary and adjustment of bolus doses instructions according to the randomization group. They have to apply these instructions for 3 months. At the end of 3 months, the study groups will be under glucose monitoring during two weeks in the Outpatient Clinic but returns to the investigational site in hospital to download data from the continuous measurement of glucose. In addition, we propose a period of extension similar to that of the main period, namely 3 months of application of dietetic and adaptation of bolus doses instructions and 2 weeks of continuous measurement of glucose.

During each 2 weeks period will be assessed specific glucose parameters in the post-prandial period over 4hours (glycemic sensor values in the glucose range between 70-140 mg / dl, glycemic sensor values in the glucose range between 140 -180 mg /dl and > 180 mg /dl) after taking each meal during the 13 days of Glucose Continuous Measurement (GCM), average daily glucose per meal, average blood glucose over the 13-day period after each meal.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 2021
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 1 diabetic patient for more than one year, practicing functional insulin for at least 3 months but not more than 5 years

- Patient treated with external insulin pump (Medtronic or Omnipod pump)

- Patient performing intermittent blood glucose monitoring by the continuous interstitial glucose measurement system (Freestyle Libre) and who regularly wears this device with an achievement of at least 4 scans per day to obtain at least 90% of the possible values

- Patient with HbA1c =10.0% less than 3 months

- Patient with a willingness and ability to comply with study requirements and schedule of visits

- Patient who received complete information and signed informed consent

Exclusion Criteria:

- Patient with contraindication for rapid or ultra-rapid insulin analogues

- Patient for whom a change of insulin in the next 3 to 6 months is planned

- Women of childbearing age who do not have effective contraception

- Women who are pregnant or breast feeding or plan on becoming pregnant during the study

- Patient taking medication that interferes with interpretation of study results such as chronic corticosteroid therapy

- Patient with a chimio - or radiotherapy is in progress or is planned

- Patient abusing substances

- Patient who participated in another clinical study in the four weeks prior to inclusion

- Patient with or suspected of having any physical, psychological or cognitive disorders interfering with adherence to insulin therapy by pump, or compliance with dietary advice, or completion of the patient's diary

- Patient unable to comply with clinical guidelines, and unable to comply with 3-month follow-up

- Patient unable to understand information, to sign informed consent or to manage glycemic sensor

Study Design


Related Conditions & MeSH terms


Intervention

Other:
New functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
functional insulin therapy
the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT

Locations

Country Name City State
France Service d'Endocrinologie-Métabolisme et Diabétologie-Nutrition Besançon
France Service d'endocrinologie et maladies métaboliques Dijon
France Service d'Endocrinologie, Diabétologie et Nutrition Nancy
France Service Endocrinologie Diabète Nutrition Reims
France Structure d'Endocrinologie, Diabète et Nutrition Strasbourg
France Service de diabétologie, maladies métaboliques et nutrition Toulouse

Sponsors (6)

Lead Sponsor Collaborator
Central Hospital, Nancy, France Central Hospital, Besançon, France, Central Hospital, Dijon, France, Central Hospital, Reims, France, Central Hospital, Strasbourg, France, Central Hospital, Toulouse, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The ratio of normoglycemia values to total glucose values The ratio (expressed as a%) of the number of normoglycemia values over the total number of values collected over the 13-day period of the glucose monitoring at 14 weeks since the patient randomization
Secondary Continuous Glucose Measurement (CGM) Specific glycemic parameters in the post-prandial period over 4h (glycemic sensor values in the blood glucose range between 70-140 mg / dl, glycemic sensor values in the blood glucose area between 140 - 180 mg / dL and> 180 Mg / dl) after taking each meal during the 13 days of CGM, average daily glucose per meal, average blood glucose over the 13-day period after each meal at 14 weeks and at 28 weeks since the patient randomization
Secondary HbA1c HbA1C dosage to assess glycemic control at 14 weeks and at 28 weeks since the patient randomization
Secondary Sensor wearing time Sensor wearing time over the 3-month period and the 13-day CGM recording period 12 weeks, 14 weeks, 26 weeks and 28 weeks since the patient randomization
Secondary Number of sensor scans Number of sensor scans performed by the patient with corresponding time periods 14 weeks and 28 weeks since the patient randomization
Secondary Number of boluses performed Number of boluses performed over the 13-day period of the CGM at 14 weeks and at 28 weeks since the patient randomization
Secondary Satisfaction of the patient with regard to his treatment Patient satisfaction assessed by the DTSQs (status) and DTSQc (change) at inclusion, at 12 weeks and 26 weeks since randomisation
Secondary Usability of the insulin pump Evaluate the use of pump functions by patient ex. Bolus calculator, Temporary base rate 14 weeks and 28 weeks since the patient randomization
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A
Recruiting NCT05737654 - The Effect of Exercise on Metabolic Parameters, Anthropometric Measurement Values and Quality of Life N/A